135 related articles for article (PubMed ID: 16267010)
1. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor.
Ho R; Minturn JE; Hishiki T; Zhao H; Wang Q; Cnaan A; Maris J; Evans AE; Brodeur GM
Cancer Res; 2005 Nov; 65(21):9868-75. PubMed ID: 16267010
[TBL] [Abstract][Full Text] [Related]
2. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
3. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
[TBL] [Abstract][Full Text] [Related]
4. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
5. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
7. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
8. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
10. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
Premkumar DR; Arnold B; Pollack IF
Mol Carcinog; 2006 May; 45(5):288-301. PubMed ID: 16550610
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Bishop PC; Myers T; Robey R; Fry DW; Liu ET; Blagosklonny MV; Bates SE
Oncogene; 2002 Jan; 21(1):119-27. PubMed ID: 11791182
[TBL] [Abstract][Full Text] [Related]
13. Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells.
Yang CM; Lin MI; Hsieh HL; Sun CC; Ma YH; Hsiao LD
J Cell Physiol; 2005 Jun; 203(3):538-46. PubMed ID: 15573401
[TBL] [Abstract][Full Text] [Related]
14. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor.
Matsuda K; Idezawa T; You XJ; Kothari NH; Fan H; Korc M
Cancer Res; 2002 Oct; 62(19):5611-7. PubMed ID: 12359775
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
16. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Memon AA; Sorensen SB; Nexo E
Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]